

92 underrepresentation of non-European populations in genetic research, this study provides an

and the state of th

93 essential assessment of PRS utility in diverse groups, thereby contributing to more equitable and

94 accurate genetic risk assessment in MS.

95

⁹⁶**Methods**

⁹⁷**Study design and inclusion criteria**

98 We conducted a cross-sectional genetic study within the All of Us Research Program⁸, an ongoing 99 study in the US that aims to enroll 1 million Americans aged 18 and older. All of Us does not focus on 100 any particular disease or health status and emphasizes recruitment of groups that have been 101 historically underrepresented in biomedical research. All of Us collects baseline health surveys at 102 enrollment and uses several means to collect longitudinal health data, including continuous 103 abstraction of EHR data in the form of billing codes, laboratory and medication data, radiology reports, 104 and linkage with other data sources, such as national death indexes, pharmacy data, health care 105 claims data, and geospatially linked environmental data. The All of Us data used for this analysis were 106 collected between May 2018 and July 2023. Data from All of Us (https://www.researchallofus.org) is 107 available to researchers by application. The All of Us institutional review board approved the study 108 protocol for this study. All participants or their legally designated surrogates provided written informed 109 consent. In the present nested study, we included participants with both whole genome sequencing 110 (WGS) data and EHR data.

¹¹²**Genomic data**

113 DNA was isolated from blood and saliva samples obtained at dedicated research centers across the

114 US, and WGS data were generated as described previously⁹. WGS data were quality controlled

115 centrally using standardized pipelines that follow the most up-to-date standards in the field.

¹¹⁷**Genetic ancestry ascertainment**

118 Ancestry was ascertained centrally by the All of Us team using principal components analysis on

119 WGS data by comparing participants with reference datasets from diverse populations. Each

120 participant was assigned to: African, East Asian, South Asian, West Asian, European, L/A or Other.

121 For the rest of the analysis, we only included participants belonging to the three largest ancestry

122 groups: European, African, and L/A.

¹²⁴**Exposure ascertainment**

- 125 Our exposure of interest was polygenic susceptibility to MS modeled through a PRS, a well-
- 126 established tool in statistical genetics that estimates an individual's genetic burden across numerous
- 127 genetic risk variants.¹⁰ For a given study participant, the polygenic risk score is the sum of the product
- 128 of the risk allele counts for each variant multiplied by the allele's reported effect on MS. The score
- 129 used genetic information on 282 independent genetic risk variants known to be associated with higher
- 130 risk of MS. These genetic risk variants are single nucleotide polymorphisms with a minor allele
- 131 frequency >1%, independent (r2, a measure of the correlation between variants, <0.1), biallelic
- ¹³²(involve two alleles only) and associated with the risk of MS at genome-wide levels (P<5x10-8),
- 133 following best practices for PRS generation.³
-

¹³⁵**Outcome assessment**

- 136 Corresponding ICD-10, and Systemized Nomenclature of Medicine (SNOMED) codes were used to
- 137 ascertain MS. Relative to baseline assessment, both prevalent and incident MS events were counted.
-

¹³⁹**Statistical analysis**

¹⁴⁰We present discrete variables as counts (percentage [%]) and continuous variables as mean 141 (standard deviation [SD]) or median (interquartile range [IQR]), as appropriate. Unadjusted 142 comparisons were made using chi-square tests for discrete variables and t or ANOVA tests, as 143 appropriate, for continuous variables. The three genetic ancestries considered (European, African, 144 L/A) were randomly sampled to obtain three populations of equivalent sizes. In each population, we 145 normalized the PRS (by subtracting the mean and dividing by the standard deviation) and divided it 146 into quintiles to establish five risk categories (very low, low, intermediate, high and very high polygenic 147 risk). To assess the relationship between the PRS and the risk of MS in each population, we used 148 multivariable logistic regression models adjusting for age, sex, and the first four genetic principal 149 components.

- 150
-

¹⁵¹**Results**

¹⁵²**Cohort characteristics**

153 Of 413,457 participants included in the All of Us Research Program, 103,125 did not have EHR data,

¹⁵⁴137,179 did not have WGS data, and 173,153 were included in our analysis (mean age: 51.6 (SD:

¹⁵⁵17), 60% female). The distribution of genetic ancestry was as follows: 95,971 (55.4%) participants of

¹⁵⁶European, 37,674 (21.8%) of African, 32,428 (18.7%) of L/A, 4,040 (2.3%) of East Asian, 2,365

¹⁵⁷(1.4%) of South Asian, and 675 (0.4%) of Middle Eastern genetic ancestry (Table 1). To obtain three

158 populations of equal sizes, we randomly sampled 32,428 participants from the African and European

- 159 populations to match the number of L/A participants.
- \overline{a}

¹⁶¹**Unadjusted analysis**

162 In each sample of 32,428 participants, there were 327 (1.0%) MS cases in the European group, 183

163 (0.56%) in the African group, and 150 (0.46%) in the L/A group. In the European population, the

164 proportion of MS cases ranged from 0.66% in the lowest PRS quintile to 1.59% in the highest PRS

165 quintile (p-value < 0.001 - Figure 1). In the African population, the proportion of MS cases did not

166 increase consistently across PRS categories with the same strength. The smallest proportion (0.45%)

167 occurred in the intermediate (3rd) PRS quintile, while the highest (0.82%) was in the highest PRS

168 quintile (p-value: 0.06). In the L/A population, the proportion of MS cases increased by PRS quintile,

169 ranging from 0.23% in the lowest quintile to 0.63% in the highest (p-value < 0.001).

¹⁷¹**Adjusted analysis**

172 In multivariable logistic regression adjusting for age, sex, and genetic principal components, we found

173 that the PRS provided effective risk stratification in the European population. The odds of MS

174 increased by 51% (Odds Ratio: 1.51, 95% CI: [1.03-2.25]) in the intermediate PRS quintile and by

175 141% (OR: 2.41 [1.69-3.50]) in the highest PRS quintile compared to the lowest (test for trend p-

176 value: <0.0001 - Figure 2). In the African population, the PRS did not significantly stratify participants

177 into different MS risk categories (test-for-trend p-value: 0.10). Conversely, in the L/A population, the

178 PRS effectively stratified risk across several categories. The odds of MS increased by 85% (Odds

179 Ratio: 1.85, 95% CI: [1.00-3.56]) in the intermediate PRS quintile and by 156% (OR: 2.56 [1.45-4.78])

180 in the highest quintile compared to the lowest (test-for-trend p-value: 0.0004).

¹⁸²**Discussion**

resultation of the contract of

183 In this study, we evaluated the effectiveness of a PRS for MS across different genetic ancestries using 184 data from the All of Us Research Program. Our findings reveal significant disparities in the utility of the 185 PRS among European, African, and L/A populations, highlighting the necessity for tailored genetic risk 186 prediction tools in diverse populations.

187

188 The PRS effectively stratified MS risk in European and L/A individuals, with higher PRS quintiles 189 corresponding to significantly increased odds of MS. This confirms the robustness of PRS derived 190 from predominantly European GWAS data for these groups. Specifically, individuals in the highest 191 PRS quintile had significantly elevated odds of developing MS compared to those in the lowest 192 quintile, consistent with previous studies demonstrating the potential of PRS in risk stratification and 193 early disease identification^{2,11}.

195 Conversely, the PRS did not significantly stratify MS risk among individuals of African ancestry. This 196 discrepancy may stem from several factors. Primarily, the limited representation of African populations 197 in existing GWAS likely results in PRS that are less applicable to this group¹². The genetic variants 198 contributing to MS risk in Europeans may not have the same effect in African populations, indicating 199 differences in the genetic architecture of MS across ancestries¹³. Additionally, gene-environment 200 interactions could play a role; genetic variants might interact with environmental factors differently 201 across populations, affecting disease risk in ways that a PRS developed in one population cannot 202. capture¹⁴. For instance, lifestyle, diet, and exposure to certain environmental factors can vary widely 203 between populations, influencing how genetic predispositions manifest as disease. Moreover, African 204 populations possess greater genetic diversity compared to European populations^{15,16}. This diversity 205 means the distribution of genetic variants is broader, including many that may be rare or absent in ²⁰⁶European populations. As a result, a PRS developed using European data may not account for the full 207 range of genetic factors influencing MS risk in African populations. This genetic diversity complicates 208 the direct application of PRS across different ancestries, necessitating the development of population-209 specific PRS to ensure accurate and equitable risk prediction.

210

211 Our study also highlights the importance of utilizing large, diverse datasets like the All of Us Research 212 Program to evaluate genetic tools' performance across populations. Such datasets are invaluable for

and the state of th

213 understanding complex diseases' genetic basis in diverse groups and developing inclusive genetic 214 risk prediction models.

216 This study has several limitations that warrant consideration. Firstly, the absolute risk of MS in the 217 population is low, which may limit the practical utility of the PRS as a stand-alone screening tool. 218 Given the multifactorial nature of MS, a comprehensive screening approach that incorporates genetic, 219 environmental, and lifestyle factors may be necessary to more accurately identify individuals at risk. 220 Additionally, the performance of the PRS in the All of Us dataset was lower compared to its 221 performance in other large datasets, such as the UK Biobank, even when considering individuals of European ancestry only². This discrepancy suggests that specific factors or characteristics unique to 223 the All of Us dataset, beyond genetic ancestry, may influence PRS performance. Factors such as 224 differences in data collection methods, population heterogeneity, or unmeasured environmental
225 influences could contribute to this variation. influences could contribute to this variation. 226 227 In conclusion, while the PRS for MS is effective in European and L/A populations, it is less effective 228 for African ancestry individuals. This emphasizes the urgent need for inclusive genetic research and 229 the development of ancestry-specific PRS to ensure equitable benefits from genetic risk prediction 230 and personalized healthcare. Future studies should focus on expanding genetic diversity in research 231 cohorts, improving underrepresented populations' representation in GWAS, and refining PRS 232 methodologies to enhance their applicability across all populations, ultimately advancing the goal of 233 personalized medicine for all. ²³⁵**Data availability statement** 236 This study used data from the All of Us Research Program's Controlled Tier Dataset C2022Q4R9 and 237 Registered Tier Dataset R2022Q4R9, available to authorized users on the Researcher Workbench via 238 www.allofus.nih.gov. All data access and analyses were conducted within a secure informatic

239 workspace provided by the National Institutes of Health.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.11.24308714;](https://doi.org/10.1101/2024.06.11.24308714) this version posted June 12, 2024. The copyright holder for this preprint

References

- 1. Dobson R, Giovannoni G. Multiple sclerosis a review. *Eur J Neurol*. 2019;26(1):27-40. doi:10.1111/ene.13819
- 2. Shams H, Shao X, Santaniello A, et al. Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. *Brain*. 2023;146(2):645-656. doi:10.1093/brain/awac092
- 3. INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science*. 2019;365(6460):eaav7188. doi:10.1126/science.aav7188
- 4. Loginovic P, Wang F, Li J, et al. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis. *Nat Commun*. 2024;15(1):1415. doi:10.1038/s41467-024-44917-9
- 5. Choi SW, Mak TSH, O'Reilly PF. A guide to performing Polygenic Risk Score analyses. *Nat Protoc*. 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1
- 6. Natarajan P, Young R, Stitziel NO, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. *Circulation*. 2017;135(22):2091-2101. doi:10.1161/CIRCULATIONAHA.116.024436
- 7. Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell*. 2019;179(3):589-603. doi:10.1016/j.cell.2019.08.051
- 8. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. *N Engl J Med*. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
- 9. Devaney S. All of Us. *Nature*. 2019;576(7785):S14-S17. doi:10.1038/d41586-019-03717-8
- 10. Vaura F, Kauko A, Suvila K. Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk. *Hypertens Dallas Tex*. 1979;2021;77(4):1119-1127. doi:10.1161/HYPERTENSIONAHA.120.16471
- 11. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. *Nat Rev Cardiol*. Published online November 22, 2021:1-11. doi:10.1038/s41569-021-00638-w
- 12. Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse populations. *Nat Genet*. 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7
- 13. Beecham AH, Amezcua L, Chinea A, et al. The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. *Mult Scler*. 2020;26(11):1329-1339. doi:10.1177/1352458519863764
- 14. Virolainen SJ, VonHandorf A, Viel KCMF, Weirauch MT, Kottyan LC. Gene–environment interactions and their impact on human health. *Genes Immun*. 2023;24(1):1-11. doi:10.1038/s41435-022-00192-6
- 15. Pereira L, Mutesa L, Tindana P, Ramsay M. African genetic diversity and adaptation inform a precision medicine agenda. *Nat Rev Genet*. 2021;22(5):284-306. doi:10.1038/s41576-020- 00306-8
- 16. Yu N, Chen FC, Ota S, et al. Larger genetic differences within africans than between Africans and Eurasians. *Genetics*. 2002;161(1):269-274.

Tables and figures (3 max)

Table 1. Cohort characteristics

Figure 1. Proportions of MS cases by PRS quintile in European, African, and L/A ancestry populations

Figure 2. Adjusted odds ratios of MS diagnosis by PRS quintile in European, African, and L/A ancestry populations

